Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Studying samples of cerebrospinal fluid from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.

PURPOSE: This laboratory study is studying cerebrospinal fluid proteins and angiogenesis proteins in young patients with newly diagnosed central nervous system tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Stored Tumor Samples in Young Patients With Brain Tumors

NCT00897286

Brain and Central Nervous System Tumors

TERMINATED

Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research

NCT01556178

Hydrocephalus

COMPLETED

Natural History of and Specimen Banking for People With Tumors of the Central Nervous System

NCT02851706

Brain Cancer Brain Tumor Spine Cancer +2 more

COMPLETED

A-protein Levels in Adult and Pediatric Brain Tumor Patients

NCT00165542

Malignant Childhood Central Nervous System Neoplasm

COMPLETED

Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors

NCT00005083

Brain and Central Nervous System Tumors

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Investigate the feasibility of centrally collecting and processing high-quality cerebrospinal fluid (CSF) samples from pediatric patients with newly diagnosed central nervous system tumors for proteomic studies.
* Identify protein markers that might indicate the presence of a brain tumor using CSF samples collected from these patients.

OUTLINE: This is a multicenter study.

Patients undergo cerebrospinal fluid (CSF) collection from any or all of the following 5 sites: lumbar, cervical, ommaya, intra-operative (ventricular, cisternal), and/or external ventricular drain. CSF is obtained within 8 weeks of diagnosis but prior to (or concurrent with) the initiation of any post-operative therapy (excluding corticosteroids).

CSF samples are examined for proteomic biomarkers by 2D gel electrophoresis, low-mass fingerprinting, and stable isotope labeling.

PROJECTED ACCRUAL: A total of 99 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain and Central Nervous System Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pediatric CNS tumor patients

Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed CNS tumors of any of the following histologies:

* Diffuse pontine gliomas\*
* Focal/infiltrative tumors, including any of the following:

* High- and low-grade gliomas
* Gangliogliomas
* Ependymomas
* Oligodendrogliomas
* Craniopharyngioma
* Dysembryoplastic neuroepithelial tumors
* Other low-grade neoplasms
* Optic pathway gliomas\*
* Seeding tumors, including any of the following:

* Germ cell tumors (germinomas and nongerminomas)
* Embryonal tumors, including any of the following:

* Medulloblastoma
* Pineoblastoma
* Supratentorial primitive neuroectodermal tumors
* Atypical teratoid/rhabdoid tumor
* Other embryonal tumors NOTE: \*Histological requirement waived
* Newly diagnosed disease
* Cerebrospinal fluid (CSF) obtained as part of CSF diversion, initial diagnosis/staging, or administration of intrathecal chemotherapy (at the initiation of postoperative therapy)

PATIENT CHARACTERISTICS:

* Less than 22 years of age

PRIOR CONCURRENT THERAPY:

* No prior radiotherapy or chemotherapy
* Prior corticosteroids allowed

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No